FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1895-1896 December 16, 1993 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Cooper, D. A. PubMed Citation

To the Editor: Cooper et al. (July 29 issue)¹ conclude that zidovudine confers benefits that last "more than 2 1/2 years" in asymptomatic patients with HIV infection and more than 400 CD4+ cells per cubic millimeter.

The authors use an "on-treatment" approach to the analysis, as evidenced by the fact that "data were censored three months after the termination of blinded treatment with the study medication." For a true intention-to-treat analysis, this approach should be supplemented with analyses in which follow-up information is not censored after the termination of blinded treatment². These analyses should consider the original primary end . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Altman, D. G., Cuzick, J., Peto, J., Cooper, D. A., Gatell, J. M. (1994). More on Zidovudine in Asymptomatic HIV Infection. NEJM 330: 1758-1759 [Full Text]